ES2194832T3 - Formulaciones de ditiazem con absorcion controlada. - Google Patents

Formulaciones de ditiazem con absorcion controlada.

Info

Publication number
ES2194832T3
ES2194832T3 ES88309665T ES88309665T ES2194832T3 ES 2194832 T3 ES2194832 T3 ES 2194832T3 ES 88309665 T ES88309665 T ES 88309665T ES 88309665 T ES88309665 T ES 88309665T ES 2194832 T3 ES2194832 T3 ES 2194832T3
Authority
ES
Spain
Prior art keywords
hours
controlled absorption
ditiazem
ditizen
filmogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88309665T
Other languages
English (en)
Inventor
Edward James Geoghegan
Seamus Mulligan
Donald Eugene Panoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE872790A external-priority patent/IE872790L/xx
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of ES2194832T3 publication Critical patent/ES2194832T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACION DE PILDORAS DE DITIAZEN DE ABSORCION CONTROLADA PARA ADMINISTRACION ORAL, QUE COMPRENDE UN NUCLEO DE DITIAZEN O UNA SAL SUYA FARMACEUTICAMENTE ACEPTABLE, EN ASOCIACION CON UN ACIDO ORGANICO Y UNA MEMBRANA DE VARIAS CAPAS, RODEANDO EL NUCLEO Y CONTIENE UNA PROPORCION IMPORTANTES DE UN POLIMERO SINTETICO INSOLUBLE EN AGUA, FILMOGENO Y ACEPTABLE FARMACEUTICAMENTE, Y OPCIONALMENTE UNA CANTIDAD PEQUEÑA DE UN POLIMERO SINTETICO SOLUBLE EN AGUA, FILMOGENO Y ACEPTABLE PARA USO FARMACEUTICO. EL NUMERO DE CAPAS DE LA MEMBRANA Y LA PROPORCION DE POLIMERO SOLUBLE A INSOLUBLE, CUANDO AQUEL ESTA PRESENTE, PERMITEN LA LIBERACION DE DITIAZEM DESDE LA PILDORA A UNA VELOCIDAD QUE PERMITE SU ABSORCION CONTROLADA EN NO MENOS DE 12 HORAS DESPUES DE LA ADMINISTRACION ORAL. LAS PILDORAS TIENEN UNA VELOCIDAD DE DISOLUCION IN VITRO TAL QUE NO MAS DEL 35% DEL DITIAZEN TOTAL SE LIBERA DESPUES DE 2 HORAS, Y NO MAS DEL 60% SE LIBERA DESPUES DE 4 HORAS, ALCANZANDOSE EL 100% NO ANTES DE 8 HORAS DESPUES DELTRATAMIENTO (SEGUN EL METODO DE LA XXI FARMACOPEA ESTADOUNIDENSE EN CLK O.O5M, A PH7).
ES88309665T 1987-10-16 1988-10-14 Formulaciones de ditiazem con absorcion controlada. Expired - Lifetime ES2194832T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IE279187 1987-10-16
IE872790A IE872790L (en) 1987-10-16 1987-10-16 Diltiazem formulation
IE315887 1987-11-20
IE82288 1988-03-18

Publications (1)

Publication Number Publication Date
ES2194832T3 true ES2194832T3 (es) 2003-12-01

Family

ID=27452034

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88309665T Expired - Lifetime ES2194832T3 (es) 1987-10-16 1988-10-14 Formulaciones de ditiazem con absorcion controlada.

Country Status (10)

Country Link
EP (2) EP0856313A1 (es)
JP (1) JPH07116044B2 (es)
KR (1) KR970001656B1 (es)
AT (1) ATE241987T1 (es)
AU (2) AU615221B2 (es)
DE (1) DE3856555T2 (es)
DK (1) DK175591B1 (es)
ES (1) ES2194832T3 (es)
NZ (1) NZ226575A (es)
PT (1) PT88776B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
ZA933725B (en) * 1992-05-28 1993-12-15 Elan Corp Plc Tablet formulation
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
NZ270078A (en) * 1994-12-06 1998-05-27 Bernard Charles Sherman Diltiazem hydrochloride formulation comprising beads with immediate, intermediate, and delayed release dissolution profiles
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US7108866B1 (en) * 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
WO2001054671A1 (fr) * 2000-01-27 2001-08-02 Tanabe Seiyaku Co., Ltd. Preparation a liberation prolongee et son procede de fabrication
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
DK3609472T3 (da) 2018-06-18 2021-04-06 Kashiv Specialty Pharmaceuticals Llc Forlænget frigivelsessammensætning indeholdende pyridostigmin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition

Also Published As

Publication number Publication date
NZ226575A (en) 1991-01-29
EP0856313A1 (en) 1998-08-05
DK575688A (da) 1989-04-17
EP0320097A1 (en) 1989-06-14
EP0320097B1 (en) 2003-06-04
JPH01132521A (ja) 1989-05-25
JPH07116044B2 (ja) 1995-12-13
AU615221B2 (en) 1991-09-26
ATE241987T1 (de) 2003-06-15
AU634660B2 (en) 1993-02-25
PT88776B (pt) 1992-12-31
DK575688D0 (da) 1988-10-14
DK175591B1 (da) 2004-12-13
AU2377588A (en) 1989-06-08
AU7943591A (en) 1991-09-12
DE3856555T2 (de) 2004-04-29
KR890006240A (ko) 1989-06-12
KR970001656B1 (ko) 1997-02-13
DE3856555D1 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
ES2189803T3 (es) Procedimiento.
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
NO890194L (no) Galenisk middel.
ES2054174T3 (es) Preparado farmaceutico de particulas para via oral que se liberan rapidamente con un sabor desagradable enmascarado.
NO174412C (no) Fremgangsmåte for fremstilling av en farmasöytisk formulering med programmert frigjöring for oral anvendelse
ATE276767T1 (de) Ein physiologisch wirksames polypeptid enthaltende pharmazeutische zusammensetzung
ATE19589T1 (de) Pharmazeutische dreilagen-filmpraeparate mit lang anhaltender wirkung.
CO4750658A1 (es) Formulaciones farmaceuticas y procedimientos que comprenden amoxicilina y una sal de acido clavulanico
ES2074124T5 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
DE69100991D1 (de) Pharmazeutische formulierungen.
ES2733044T1 (es) Composición farmacéutica que contiene oxicodona y naloxona
HUP0204159A2 (hu) Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására
ES2160693T3 (es) Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona.
YU215090A (sr) Formulacija u obliku pilule za kontrolisano oslobađanje
ZA94856B (en) Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
DK158788A (da) Framaceutisk praeparat med langsom frigivelse
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
AR033688A1 (es) Composicion parenteral reconstituible
DE3856555D1 (de) Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
AR038394A2 (es) Forma de dosificacion oral de liberacion espacialmente retardada
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.